Myelodysplastic Syndromes
The latest news, research, and perspectives in myelodysplastic syndromes (MDS). Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.
Advertisement
The EC approval of luspatercept was based on results from the phase II BEYOND study.
Treatment of LR-MDS remains an unmet need and goals of therapy should extend beyond transfusion independence.
MDS/AML are among independent predictors of COVID-19 treatment failure.
Oxidized mitochondrial DNA can “prime” MDS HSPCs for inflammasome activation.
Low-risk MDS can have high-risk features, but current MDS prognostic scoring systems may not capture key risk variables.
While the fifth edition “softened” the boundary between MDS and AML, it retains the 20% blast cutoff to define AML.
Advertisement
Exposure to thalidomide analogs is associated with TP53 mutations in patients with therapy-related myeloid neoplasms.
Luspatercept reduced RBC transfusion units and visits in patients with lower-risk MDS with ring sideroblasts.
A panel recently made a consensus proposal to revise the IWG response criteria for higher-risk MDS.
The U.S. FDA granted Fast Track Designation to tamibarotene, an oral selective RARα agonist, for higher-risk MDS.
Sanam Loghavi, MD, chats with The HemOnc Pulse host Chadi Nabhan, MD, MBA, FACP, about why 2022 was a major year for MDS.
A participant’s death led to a voluntary pause of a phase I/II trial evaluating MGTA-117 in relapsed/refractory AML and ...
Long-term safety data for luspatercept showed no new safety signals in lower-risk MDS.
Venetoclax plus azacitidine provided “clinically meaningful benefits” in R/R/ MDS post-HMA failure.
Researchers have developed and externally validated a clinical-molecular prognostic model for risk stratification in MDS.
Patients with MDS who received active therapy soon after their diagnosis had better outcomes than those who did not.
DocMatter members weigh in on the use of venetoclax in patients with higher-risk myelodysplastic syndromes.
Survival rates for MDS/MPN overlap syndromes vary significantly by clinical entity.
A phase III trial confirmed the efficacy of lenalidomide in transfusion-dependent MDS patients.
MDS patients with del5q and one additional non-del20q cytogenetic abnormality are at higher risk.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
670 Madison Ave.
Manalapan, NJ 07726